<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0003613'>Antiphospholipid antibody</z:hpo> syndrome (APS) is a recently defined <z:e sem="disease" ids="C0004364" disease_type="Disease or Syndrome" abbrv="">autoimmune disorder</z:e> characterized by recurrent vascular thromboses or recurrent pregnancy morbidity; these features are linked to the presence in blood of autoantibodies against negatively charged <z:chebi fb="1" ids="16247">phospholipids</z:chebi> or <z:chebi fb="0" ids="16247">phospholipid</z:chebi>-binding proteins </plain></SENT>
<SENT sid="1" pm="."><plain><z:mp ids='MP_0005048'>Thrombosis</z:mp> can occur in any tissue, in veins, arteries, or the microvasculature </plain></SENT>
<SENT sid="2" pm="."><plain>Pregnancy morbidity in APS includes <z:e sem="disease" ids="C0000786" disease_type="Disease or Syndrome" abbrv="">miscarriages</z:e> or <z:hpo ids='HP_0001622'>premature birth</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Criteria that define the major clinical and laboratory features of APS were published in 1999 </plain></SENT>
<SENT sid="4" pm="."><plain>In patients with <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> and prior <z:mp ids='MP_0005048'>thrombosis</z:mp> or pregnancy morbidity, there is a high risk of recurrence that persists as long as <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> occur in blood </plain></SENT>
<SENT sid="5" pm="."><plain>This risk for recurrence of <z:mp ids='MP_0005048'>thrombosis</z:mp> or pregnancy morbidity is greatly reduced by preventive <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> therapy </plain></SENT>
<SENT sid="6" pm="."><plain>Patients presenting with <z:mp ids='MP_0005048'>thrombosis</z:mp> in APS are initially managed in much the same way as are patients with vascular <z:mp ids='MP_0005048'>thrombosis</z:mp> owing to other causes </plain></SENT>
<SENT sid="7" pm="."><plain>However, in patients with APS, high-intensity anticoagulation is usually needed to prevent recurrences of <z:mp ids='MP_0005048'>thrombosis</z:mp> </plain></SENT>
<SENT sid="8" pm="."><plain><z:mp ids='MP_0005048'>Thrombosis</z:mp> in APS is often multifactorial, as with non-APS <z:mp ids='MP_0005048'>thrombosis</z:mp> </plain></SENT>
<SENT sid="9" pm="."><plain>Therefore, in <z:hpo ids='HP_0000001'>all</z:hpo> patients with APS, other reversible risk factors for <z:mp ids='MP_0005048'>thrombosis</z:mp> should be sought </plain></SENT>
<SENT sid="10" pm="."><plain>The pregnancy outcome of women with APS who have had prior <z:e sem="disease" ids="C0000786" disease_type="Disease or Syndrome" abbrv="">miscarriages</z:e> is greatly improved by treatment during pregnancy with a combination of <z:chebi fb="5" ids="28304">heparin</z:chebi> and low-dose aspirin </plain></SENT>
</text></document>